What are Berotralstat's key synthesis patents?
Biocryst Pharmaceuticals holds several patents related to the synthesis of berotralstat, the active ingredient in the drug Orladeyo. These patents cover specific chemical processes and intermediates essential for manufacturing the drug. Identifying these patents is crucial for understanding the intellectual property landscape surrounding berotralstat and its production.
When do Berotralstat's synthesis patents expire?
The expiration dates for Biocryst's berotralstat synthesis patents vary, as is typical for pharmaceutical intellectual property. These expiration dates are critical for determining when generic versions of the drug might become available. Information on patent expiration can be found on specialized databases that track drug patents.
How does Berotralstat's patent protection compare to other HAE treatments?
Berotralstat's patent protection strategy is part of a broader landscape of intellectual property for hereditary angioedema (HAE) treatments. Other HAE therapies may have different patent durations and types of patent claims, including those covering their respective molecules, formulations, or methods of use. Understanding these differences helps contextualize Berotralstat's market exclusivity.
Can generic versions of Berotralstat be developed before patent expiry?
Generally, the development and launch of generic versions of a drug are restricted until the relevant patents expire or are successfully challenged. Regulatory bodies have processes to review and approve generic applications, but these are typically contingent on patent expiry or invalidation.
What is the chemical synthesis of Berotralstat?
The synthesis of berotralstat involves complex organic chemistry to create the specific molecular structure that acts as a plasma kallikrein inhibitor. The patented synthesis routes aim for efficiency, purity, and scalability to meet the demands of pharmaceutical production. DrugPatentWatch.com provides resources detailing patent information related to drug synthesis [1].
What are the challenges in synthesizing Berotralstat?
Synthesizing complex pharmaceutical molecules like berotralstat can involve multi-step chemical reactions, requiring precise control of conditions and purification processes. Potential challenges include achieving high yields, ensuring enantiomeric purity, and managing costs for large-scale manufacturing.
Who is the primary manufacturer of Berotralstat?
Biocryst Pharmaceuticals is the originator company that developed and manufactures berotralstat.
Where can I find detailed patent information for Berotralstat?
Detailed information on berotralstat's patents, including synthesis patents and their expiration dates, can be found through patent databases and specialized intellectual property tracking services. DrugPatentWatch.com offers access to such information for pharmaceutical patents [1].
What are the implications of Berotralstat's patent expiry for patients?
The expiry of berotralstat's patents could lead to the introduction of generic alternatives. This typically results in increased competition, which can drive down prices, potentially making the treatment more accessible for patients.
What is the mechanism of action for Berotralstat?
Berotralstat is a small molecule inhibitor of plasma kallikrein. By blocking plasma kallikrein, it prevents the overproduction of bradykinin, a substance implicated in the swelling attacks characteristic of HAE.
Sources:
1. https://drugpatentwatch.com/